Zevra Therapeutics (ZVRA) Current Leases (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Current Leases came in at $406000.0 in Q1 2026, down 31.07% YoY from $589000.0 in Q1 2025, and down 3.1% on a QoQ basis from $419000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Current Leases (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Current Leases data on file, last reported at $406000.0 in Q1 2026.
- Quarterly Current Leases fell 31.07% year-over-year to $406000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $406000.0 (down 31.07% YoY) and the FY2025 annual result came in at $419000.0, changed 0.24% from the prior year.
- Current Leases retreated to $406000.0 in Q1 2026, from $419000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $596000.0 in Q2 2024 to a low of $356000.0 in Q1 2022.
- A 5-year average of $485785.7 and a median of $475000.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases soared 34.83% — and 2026, when it tumbled 31.07%.
- Tracing ZVRA's Current Leases over 5 years: stood at $480000.0 in 2022, then rose by 13.12% to $543000.0 in 2023, then declined by 22.65% to $420000.0 in 2024, then slipped by 0.24% to $419000.0 in 2025, then declined by 3.1% to $406000.0 in 2026.
- The last three Current Leases figures came in at $406000.0 (Q1 2026), $419000.0 (Q4 2025), and $441000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 626,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 626,000.00 |
| Mar 31, 2026 | 406,000.00 |
| Dec 31, 2025 | 419,000.00 |
| Sep 30, 2025 | 441,000.00 |
| Jun 30, 2025 | 525,000.00 |
| Mar 31, 2025 | 589,000.00 |
| Dec 31, 2024 | 420,000.00 |
| Sep 30, 2024 | 540,000.00 |
| Jun 30, 2024 | 596,000.00 |
| Mar 31, 2024 | 583,000.00 |
| Dec 31, 2023 | 543,000.00 |
| Sep 30, 2023 | 433,000.00 |
| Mar 31, 2023 | 470,000.00 |
| Dec 31, 2022 | 480,000.00 |
| Mar 31, 2022 | 356,000.00 |
| Dec 31, 2021 | 356,000.00 |
| Sep 30, 2021 | 349,000.00 |
| Jun 30, 2021 | 342,000.00 |
| Mar 31, 2021 | 336,000.00 |
| Dec 31, 2020 | 327,000.00 |